New Treatment Option for Opioid Dependence Available
Orexo announced that Zubsolv (buprenorphine and naloxone) sublingual tablets are now available in pharmacies. Zubsolv was approved by the FDA in July 2013 for the maintenance treatment of opioid dependence as part of a complete treatment plan, including counseling and psychosocial support.
Zubsolv is a schedule CIII narcotic that combines buprenorphine, an opioid (partial agonist-antagonist), and naloxone, an opioid antagonist. The higher bioavailability of Zubsolv allows for a lower dose of buprenorphine being administered which, in combination with the naloxone component, reduces the amount of available drug and the likelihood of potential misuse and diversion.
In addition, Orexo is launching RISE, a real-time, customizable support program informed by patients in recovery. It provides information about opioid dependence and resources to help facilitate conversation between patients and their chosen mentor network.
Zubsolv sublingual tablets are available in 1.4mg/0.36mg and 5.7mg/1.4mg strengths as a menthol flavor. Each Zubsolv tablet is supplied in individual unit-dose blister packages, reducing the chance of unintended pediatric exposure.
Orexo has also issued the Time and Taste Challenge, inviting patients and prescribers to register to receive demonstration placebo tablets to experience the taste and dissolve time for this formulation. The placebo tablets are for demonstration purposes only and do not contain active medication.
To register for the Time and Taste Challenge or to get more information on Zubsolv visit Zubsolv.com or call 1-855-ZUBSOLV.